Impact of prior authorizations, Dr. Price confirmation, dermatology robots, atopic dermatitis links, psoriasis and bone fractures. View this email in your browser
Dermatology World Weekly
February 1, 2017
The burden of prior authorizations: How bad is it really?

The U.S. Food and Drug Administration (FDA) has cleared the StarWalker® MaQX Q-Switched laser system to be used for treating tattoos, pigmented and vascular lesions, acne and scars, and hair reduction. Fotona, the manufacturer of the device, has indicated that the laser system will be available for purchase in the United States immediately. 

Tattoos have become increasingly popular over the years, yet dermatologists often see patients looking to remove the body art as well. Read more about the latest technology in tattoo removal in Dermatology World.

Related Links:

Experimental psoriasis drug offers better clearance

Results from a recent study published in the New England Journal of Medicine, suggest that Johnson & Johnson’s guselkumab — an anti-IL-23 therapy — may be more effective in treating psoriasis than TNF-alpha inhibitors.

Related Links:

Links to this month's issue

Sunscreen comparison
Improving access



Copyright © 2017 by the American Academy of Dermatology and American Academy of Dermatology Association. "All rights reserved." Reproduction or republication strictly prohibited without prior written permission.

You are receiving this email as part of your membership benefits with the AAD.

Unsubscribe from Dermatology World Weekly

Our address is:

Contact Us | Manage your email preferences | Opt out of all emails